BofA warns Fed risks policy mistake with early rate cuts
Chief Medical (TASE:BLWV) Officer of Tenaya Therapeutics (NASDAQ:TNYA), Whittemore Tingley, sold a total of 5,053 shares of common stock on August 18, 2025. The sales were executed in three separate transactions, with the price per share at $1.253. The stock, currently trading near InvestingPro’s Fair Value estimate, has shown significant volatility with a 66% gain in the past week and a beta of 3.02.
The sales, which totaled approximately $6,329, were executed to cover tax withholding obligations related to the vesting of restricted stock units. The prices for the shares sold ranged from $1.18 to $1.32. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.0 and holds more cash than debt on its balance sheet.
Specifically, Tingley sold 1,608 shares for approximately $2,014 related to restricted stock units awarded on February 15, 2023. An additional 1,608 shares were sold for around $2,014 related to restricted stock units awarded on February 23, 2024. Finally, 1,837 shares were sold for about $2,301 related to restricted stock units awarded on January 24, 2025.
Following these transactions, Tingley directly owns 172,803 shares of Tenaya Therapeutics, Inc. common stock, which includes shares that will be issued upon the vesting of restricted stock units and shares acquired through the company’s employee stock purchase plan. With six analysts recently revising earnings estimates upward, InvestingPro subscribers can access detailed insider trading patterns and 12 additional ProTips to make informed investment decisions.
In other recent news, Tenaya Therapeutics has announced significant progress in its gene therapy clinical trials. The company received positive safety endorsements from independent monitoring boards, allowing the continuation of its MyPEAK-1 trial for TN-201 and the RIDGE-1 trial for TN-401. These endorsements enable Tenaya to proceed with expansion cohorts for TN-201 and to expand and escalate dosing for TN-401. Additionally, Tenaya has completed enrollment in both dose cohorts for the MyPEAK-1 Phase 1b/2 clinical trial targeting hypertrophic cardiomyopathy. The firm also reported dosing the first patient in Cohort 2 of its RIDGE-1 Phase 1b trial for arrhythmogenic right ventricular cardiomyopathy. These developments mark important steps forward in Tenaya’s clinical research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.